Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.0% Today

What is Amylyx Pharmaceuticals?

Asset Amylyx Pharmaceuticals, Inc. (AMLX) is a pharmaceutical company listed on the NASDAQ. Today, the stock experienced a significant bearish movement in the market.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.0% on Nov 10, 2025 18:15

• AMLX stock might have experienced a bearish movement due to a securities fraud class action investigation by Grabar Law Office, causing uncertainty and negative sentiment among investors.
• The investigation and potential legal implications could have led to a lack of confidence in the company's management and financial practices, resulting in a sell-off of AMLX shares.
• Investors may be concerned about the impact of the ongoing legal issues on the company's future performance and profitability, leading to a bearish trend in the stock price.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Is Exact Sciences ( EXAS ) Stock Outpacing Its Medical Peers This Year?

Here is how Exact Sciences (EXAS) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

https://www.zacks.com/stock/news/2788511/is-exact-sciences-exas-stock-outpacing-its-medical-peers-this-year

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. ( NASDAQ: AMLX ) ; Avantor, Inc. ( NYSE: AVTR ) ; Humana Inc. ( NYSE: HUM ) ; and Maison Solutions Inc. ( NASDAQ: MSS ) : Grabar Law Office Investigates Claims on Your Behalf - Amylyx Pharmaceuticals ( NASDAQ:AMLX ) , Avantor ( NYSE:AVTR )

PHILADELPHIA, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) - Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) as securities fraud class action ...

https://www.benzinga.com/pressreleases/25/11/g48690236/notice-to-long-term-shareholders-of-amylyx-pharmaceuticals-inc-nasdaq-amlx-avantor-inc-nyse-avtr-h

Trending Today

Litecoin ($LTC) Crypto Forecast: Down 5.2% Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Down 5.0% Today

Cardano ($ADA) Crypto Forecast: Down 5.2% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 6.2% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 5.1% Today

Lemonda Inc. ($LMND) Stock Forecast: Down 5.2% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Down 5.2% Today

Kimberly-Clark Corporation ($KMB) Stock Forecast: Down 0.3% Today

Robinhood Inc. ($HOOD) Stock Forecast: Down 5.2% Today

Solana ($SOL) Crypto Forecast: Down 5.2% Today

Amylyx Pharmaceuticals Price History

17.08.2024 - AMLX Stock was up 10.3%

• Recent executive purchases of shares in Reneo Pharmaceuticals and other stocks priced below $5 could signal optimism towards the pharmaceutical sector, potentially benefiting similar companies like AMLX.
• The market's bullish trend, reflected in the Dow Jones index, likely created a favorable atmosphere for small-cap stocks such as AMLX to perform well.
• The insider buying activity may have been viewed by investors and traders as a show of support for the industry, leading to increased interest in AMLX and driving its positive movement.

27.07.2025 - AMLX Stock was up 5.1%

• AMLX stock surged as investors reacted positively to the company's strategic shift in focus from AMX0035 to avexitide and amyotrophic lateral sclerosis programs.
• The decision to halt the Phase 2b trial for AMX0035 in progressive supranuclear palsy, despite showing no benefit over placebo, was seen as a prudent move by the company to reallocate resources to more promising programs.
• The announcement of a cash runway through 2026 provided investors with confidence in the company's long-term sustainability and growth potential, contributing to the bullish sentiment surrounding AMLX stock today.

25.05.2025 - AMLX Stock was up 9.2%

• AMLX displayed significant bullish movement in the market today.
• The upward trend can be attributed to optimistic analyst views regarding the company's potential PBH treatment, which is estimated to target a $2 billion global market by 2035.
• Investor enthusiasm is likely fueled by the anticipation of Avexitide's Phase 3 trial results in the first half of 2026 and the positive outcomes seen in Phase 2 trials.
• Positive analyst initiations and coverage have also played a role in fostering a favorable outlook on AMLX, signaling increasing confidence in the company's future prospects.

18.10.2024 - AMLX Stock was up 7.1%

• The bullish movement in AMLX could be attributed to positive analyst sentiment and upgrades in the online trading sector, similar to recent developments with other companies in the industry.
• This change in outlook by analysts may have instilled confidence in investors, leading to increased buying activity and driving the stock price higher.
• The overall optimism in the online trading industry, as indicated by the analyst upgrades, likely contributed to the positive momentum seen in AMLX today.

07.04.2025 - AMLX Stock was down 5.7%

• A positive upgrade of Logitech International by a prominent Wall Street analyst possibly drew investor attention away from Amylyx Pharmaceuticals, resulting in a decline in AMLX shares.
• The favorable outlook on Logitech International could have prompted a sector shift, with investors reallocating resources from pharmaceuticals like AMLX to technology-oriented firms.
• The upgrade of Logitech International might have eclipsed any recent developments or announcements concerning Amylyx Pharmaceuticals, contributing to the stock's decline.
• Investors may be adjusting their investment portfolios influenced by changing analyst evaluations, leading to a redirection of focus from AMLX to other companies with more favorable ratings.

14.06.2025 - AMLX Stock was up 5.3%

• AMLX stock surged due to positive results from the Phase 2b trial of their drug avexitide, which showed a significant reduction in hypoglycemic events post-weight loss surgery.
• The promising data from the trial likely boosted investor confidence in the drug's potential success in the market, leading to the bullish movement in AMLX stock.
• The positive news overshadowed other market events such as the drop in PPI and Industrial Production, indicating that investors were primarily focused on the favorable trial results of avexitide.

06.10.2025 - AMLX Stock was down 5.1%

• The bearish movement in AMLX could be attributed to a class action lawsuit against the company for securities fraud, likely causing uncertainty and negative sentiment among investors.
• Concerns about the lawsuit's impact on the company's financial stability and reputation may have led to a sell-off of the stock.
• An ongoing investigation into the claims against AMLX could have intensified pressure on the stock price, as uncertainty typically results in reduced investor confidence and a decline in stock value.

10.10.2025 - AMLX Stock was down 5.0%

• AMLX stock might have experienced a bearish movement due to a securities fraud class action investigation by Grabar Law Office, causing uncertainty and negative sentiment among investors.
• The investigation and potential legal implications could have led to a lack of confidence in the company's management and financial practices, resulting in a sell-off of AMLX shares.
• Investors may be concerned about the impact of the ongoing legal issues on the company's future performance and profitability, leading to a bearish trend in the stock price.

17.09.2025 - AMLX Stock was down 5.0%

• The strong bearish movement in AMLX stock today could be attributed to profit-taking by investors after a period of solid earnings estimate revision activity.
• Despite belonging to a strong industry, the stock may have faced selling pressure due to market volatility or broader economic concerns.
• Investors might be reassessing their positions in AMLX stock, leading to a temporary decline in its market value.

12.02.2025 - AMLX Stock was up 12.4%

• Amylyx Pharmaceuticals (AMLYX) experienced a strong bullish movement.
• The positive market sentiment and the overall bullish trend in the market could have contributed to the surge in AMLYX stock.
• There were no specific negative news related to AMLYX mentioned, indicating that the bullish movement might be more driven by market factors rather than company-specific news.
• Investors might be optimistic about the future prospects of Amylyx Pharmaceuticals, leading to increased buying interest and pushing the stock price higher.

24.05.2025 - AMLX Stock was up 10.1%

• Amylyx Pharmaceuticals (NASDAQ: AMLX) experienced a strong bullish movement today.
• The upsurge in the stock's performance may be linked to a new analyst initiating a favorable outlook on the company.
• Analyst Marcus Cole from UBS commencing coverage on a positive note possibly bolstered investor confidence in AMLX.
• The optimistic analyst outlook likely played a role in driving the bullish momentum in AMLX's stock price during the day.

05.10.2025 - AMLX Stock was down 4.1%

• An investigation into claims of securities fraud might have affected investor confidence in the company's operations and financial reporting.
• The survival of the class action lawsuit could lead to legal and financial challenges for Amylyx Pharmaceuticals, creating uncertainty for investors.
• Negative developments surrounding the company may have dampened market sentiment, overshadowing potential growth prospects and contributing to the bearish movement.